Aimmune Therapeutics Stock News

LONDON--(BUSINESS WIRE)--Aimmune Therapeutics UK Ltd., a Nestlé Health Science company developing and commercialising pharmaceutical therapies to prevent, manage, and treat food and metabolic related

VEVEY, Switzerland & LONDON--(BUSINESS WIRE)--European Commission Approves Aimmune's PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU

Aimmune has agreed to be acquired by Nestle following a cash offer reflecting a premium of ~174% to the company’s pre-merger value.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.

AstraZeneca reports positive data for Phase III Farxiga trial. Aimmune Therapeutics to be acquired by Nestle.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.

Thanks to bad news for its competitor, this company behind the first FDA-approved peanut allergy treatment could be ripe for a rebound.

Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Is this battered biotech stock now a good deal for investors?

The

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that sm

Shares of DBV Technologies tumbled 8.5% in premarket trading on Wednesday, the day after the company said it had received a complete response letter from the Food and Drug Administration for its expe

Aimmune Therapeutics Inc (NASDAQ: AIMT) shares, which recovered Monday following an earnings-induced sell-off Friday, are adding to the gains.  The Aimmune Catalyst: Shares...